A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease

Lynne Shinto, Joseph Quinn, Thomas Montine, Hiroko Dodge, William Woodward, Sara Baldauf-Wagner, Dana Waichunas, Lauren Bumgarner, Dennis Bourdette, Lisa Silbert, Jeffrey Kaye

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid (ω-3 + LA) compared to placebo on oxidative stress biomarkers in AD. The primary outcome measure was peripheral F2-isoprostane levels (oxidative stress measure). Secondary outcome measures included performance on: Mini-Mental State Examination (MMSE), Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL), and Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). Thirty-nine AD subjects were randomized to one of three groups: 1) placebo, 2) ω-3, or 3) ω-3 + LA for a treatment duration of 12 months. Eighty seven percent (34/39) of the subjects completed the 12-month intervention. There was no difference between groups at 12 months in peripheral F2-isoprostane levels (p = 0.83). The ω-3 + LA and ω-3 were not significantly different than the placebo group in ADAS-cog (p = 0.98, p = 0.86) and in ADL (p = 0.15, p = 0.82). Compared to placebo, the ω-3 + LA showed less decline in MMSE (p <0.01) and IADL (p = 0.01) and the ω-3 group showed less decline in IADL (p <0.01). The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months. Because the results were generated from a small sample size, further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment in AD is warranted.

Original languageEnglish (US)
Pages (from-to)111-120
Number of pages10
JournalJournal of Alzheimer's Disease
Volume38
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Thioctic Acid
Omega-3 Fatty Acids
Alzheimer Disease
Placebos
Activities of Daily Living
F2-Isoprostanes
Oxidative Stress
Outcome Assessment (Health Care)
Sample Size
Epidemiologic Studies
Fishes
Biomarkers
Cholesterol
Pathology
Inflammation
Therapeutics

Keywords

  • Alpha-lipoic acid
  • Alzheimer's disease
  • clinical trial
  • omega-3 fatty acids

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. / Shinto, Lynne; Quinn, Joseph; Montine, Thomas; Dodge, Hiroko; Woodward, William; Baldauf-Wagner, Sara; Waichunas, Dana; Bumgarner, Lauren; Bourdette, Dennis; Silbert, Lisa; Kaye, Jeffrey.

In: Journal of Alzheimer's Disease, Vol. 38, No. 1, 2014, p. 111-120.

Research output: Contribution to journalArticle

@article{bdfa96a3e6a9427eacaeca49a404bc46,
title = "A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease",
abstract = "Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid (ω-3 + LA) compared to placebo on oxidative stress biomarkers in AD. The primary outcome measure was peripheral F2-isoprostane levels (oxidative stress measure). Secondary outcome measures included performance on: Mini-Mental State Examination (MMSE), Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL), and Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). Thirty-nine AD subjects were randomized to one of three groups: 1) placebo, 2) ω-3, or 3) ω-3 + LA for a treatment duration of 12 months. Eighty seven percent (34/39) of the subjects completed the 12-month intervention. There was no difference between groups at 12 months in peripheral F2-isoprostane levels (p = 0.83). The ω-3 + LA and ω-3 were not significantly different than the placebo group in ADAS-cog (p = 0.98, p = 0.86) and in ADL (p = 0.15, p = 0.82). Compared to placebo, the ω-3 + LA showed less decline in MMSE (p <0.01) and IADL (p = 0.01) and the ω-3 group showed less decline in IADL (p <0.01). The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months. Because the results were generated from a small sample size, further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment in AD is warranted.",
keywords = "Alpha-lipoic acid, Alzheimer's disease, clinical trial, omega-3 fatty acids",
author = "Lynne Shinto and Joseph Quinn and Thomas Montine and Hiroko Dodge and William Woodward and Sara Baldauf-Wagner and Dana Waichunas and Lauren Bumgarner and Dennis Bourdette and Lisa Silbert and Jeffrey Kaye",
year = "2014",
doi = "10.3233/JAD-130722",
language = "English (US)",
volume = "38",
pages = "111--120",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease

AU - Shinto, Lynne

AU - Quinn, Joseph

AU - Montine, Thomas

AU - Dodge, Hiroko

AU - Woodward, William

AU - Baldauf-Wagner, Sara

AU - Waichunas, Dana

AU - Bumgarner, Lauren

AU - Bourdette, Dennis

AU - Silbert, Lisa

AU - Kaye, Jeffrey

PY - 2014

Y1 - 2014

N2 - Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid (ω-3 + LA) compared to placebo on oxidative stress biomarkers in AD. The primary outcome measure was peripheral F2-isoprostane levels (oxidative stress measure). Secondary outcome measures included performance on: Mini-Mental State Examination (MMSE), Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL), and Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). Thirty-nine AD subjects were randomized to one of three groups: 1) placebo, 2) ω-3, or 3) ω-3 + LA for a treatment duration of 12 months. Eighty seven percent (34/39) of the subjects completed the 12-month intervention. There was no difference between groups at 12 months in peripheral F2-isoprostane levels (p = 0.83). The ω-3 + LA and ω-3 were not significantly different than the placebo group in ADAS-cog (p = 0.98, p = 0.86) and in ADL (p = 0.15, p = 0.82). Compared to placebo, the ω-3 + LA showed less decline in MMSE (p <0.01) and IADL (p = 0.01) and the ω-3 group showed less decline in IADL (p <0.01). The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months. Because the results were generated from a small sample size, further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment in AD is warranted.

AB - Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid (ω-3 + LA) compared to placebo on oxidative stress biomarkers in AD. The primary outcome measure was peripheral F2-isoprostane levels (oxidative stress measure). Secondary outcome measures included performance on: Mini-Mental State Examination (MMSE), Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL), and Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). Thirty-nine AD subjects were randomized to one of three groups: 1) placebo, 2) ω-3, or 3) ω-3 + LA for a treatment duration of 12 months. Eighty seven percent (34/39) of the subjects completed the 12-month intervention. There was no difference between groups at 12 months in peripheral F2-isoprostane levels (p = 0.83). The ω-3 + LA and ω-3 were not significantly different than the placebo group in ADAS-cog (p = 0.98, p = 0.86) and in ADL (p = 0.15, p = 0.82). Compared to placebo, the ω-3 + LA showed less decline in MMSE (p <0.01) and IADL (p = 0.01) and the ω-3 group showed less decline in IADL (p <0.01). The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months. Because the results were generated from a small sample size, further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment in AD is warranted.

KW - Alpha-lipoic acid

KW - Alzheimer's disease

KW - clinical trial

KW - omega-3 fatty acids

UR - http://www.scopus.com/inward/record.url?scp=84887224886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887224886&partnerID=8YFLogxK

U2 - 10.3233/JAD-130722

DO - 10.3233/JAD-130722

M3 - Article

C2 - 24077434

AN - SCOPUS:84887224886

VL - 38

SP - 111

EP - 120

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -